Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
NCT05896293Phase 2Recruiting
- Start
- Feb 2023
- Primary completion
- May 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of kisspeptin 112-121 in hypogonadotropic hypogonadism (HH). Started Feb 2023; status: recruiting.
02
Drugs
kisspeptin 112-121
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on NCT05896293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896293.